ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,621 to 4,640 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Sustained Care vs Standard Care: serious adverse events216 of 680

224 of 677

-1.3 points

-6.3 to 3.7

1,357NCT01714323

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks152 of 682

161 of 672

-1.7 points

-6.2 to 2.8

1,354NCT01468987

A Study in Participants With Type 2 Diabetes Mellitus

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Received Treatment for mCRPC and mCSPC668 of 795

536 of 558

-12.0 points

-15.0 to -9.0

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Symptomatic Skeletal-Related Event (SSRE)44 of 795

43 of 558

-2.2 points

-5.0 to 0.5

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Orchiectomy10 of 795

9 of 558

-0.4 points

-1.9 to 0.9

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With de Novo Metastasis444 of 795

240 of 558

12.8 points

7.4 to 18.1

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Were on Opioids310 of 795

332 of 558

-20.5 points

-25.7 to -15.1

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Undergone Palliative Radiology222 of 795

187 of 558

-5.6 points

-10.6 to -0.6

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Were on Bone Medication154 of 795

292 of 558

-33.0 points

-37.8 to -27.9

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: deaths from any cause343 of 795

218 of 558

4.1 points

-1.3 to 9.3

1,353NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Denosumab 60 mg Q6M vs Placebo: Number of Participants With a New Vertebral Fracture Through Month 3610 of 679

26 of 673

-2.4 points

-4.3 to -0.7

1,352NCT00089674

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Nintedanib vs Placebo: serious adverse events379 of 902

157 of 450

7.1 points

1.6 to 12.5

1,352NCT01015118

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations673 of 677

665 of 674

0.7 points

-0.4 to 2.0

1,351NCT03788967

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

HRV PCV-free Liq Group vs HRV Lyo Group: Number of Subjects With Any Unsolicited AEs201 of 677

206 of 674

-0.9 points

-5.8 to 4.0

1,351NCT03954743

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

HRV PCV-free Liq Group vs HRV Lyo Group: Number of Subjects With Any Serious Adverse Events (SAEs)39 of 677

38 of 674

0.1 points

-2.4 to 2.6

1,351NCT03954743

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

HRV PCV-free Liq Group vs HRV Lyo Group: serious adverse events39 of 677

38 of 674

0.1 points

-2.4 to 2.6

1,351NCT03954743

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Nitazoxanide vs Placebo: serious adverse events3 of 686

6 of 663

-0.5 points

-1.6 to 0.5

1,349NCT04359680

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

TDF/FTC vs Placebo: Incidence of HSV-2 During the Follow-up Period65 of 671

60 of 676

0.8 points

-2.3 to 3.9

1,347NCT00458393

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

MAGE-A3 Group vs Placebo Group: Number of Subjects With Potential Immune-mediated Diseases (pIMDs)33 of 895

23 of 450

-1.4 points

-4.1 to 0.8

1,345NCT00796445

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

MAGE-A3 Group vs Placebo Group: Number of Subjects With Any Serious Adverse Events (SAEs)129 of 895

64 of 450

0.2 points

-3.9 to 4.0

1,345NCT00796445

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=232"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=232

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01714323-sae",
        "title": "Sustained Care vs Standard Care: serious adverse events",
        "summary": "216 of 680 against 224 of 677; risk difference -1.3 points, 95% interval -6.3 to 3.7; NCT01714323, Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers",
        "record": "/library/comparisons/NCT01714323-sae",
        "nct_id": "NCT01714323",
        "kind": "serious-adverse-events",
        "participants": 1357,
        "risk_difference": {
          "value": -0.013224433052393791,
          "lower": -0.06288945848082331,
          "upper": 0.03652187124851847
        },
        "group_1": "216 of 680",
        "group_2": "224 of 677",
        "difference": "-1.3 points",
        "interval": "-6.3 to 3.7",
        "trial_title": "Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers"
      },
      {
        "id": "NCT01468987-096d7456",
        "title": "LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks",
        "summary": "152 of 682 against 161 of 672; risk difference -1.7 points, 95% interval -6.2 to 2.8; NCT01468987, A Study in Participants With Type 2 Diabetes Mellitus",
        "record": "/library/comparisons/NCT01468987-096d7456",
        "nct_id": "NCT01468987",
        "kind": "outcome",
        "participants": 1354,
        "risk_difference": {
          "value": -0.016709433040078214,
          "lower": -0.06158025772037633,
          "upper": 0.028193633276980545
        },
        "group_1": "152 of 682",
        "group_2": "161 of 672",
        "difference": "-1.7 points",
        "interval": "-6.2 to 2.8",
        "trial_title": "A Study in Participants With Type 2 Diabetes Mellitus"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=233",
  "request_id": "A0ECszlwUcJMmr38"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?